Transdermal Drug Delivery Market Growth is Driven by Ongoing Biotechnology Drugs Expansion, States Kalorama Information

12 Oct 2012 • by Natalie Aster

The market for drugs delivered through the skin by the use of patches and other technologies is expected to reach $8.1 billion in 2012. Transdermally-delivered drug products are now being marketed successfully in areas other than the popular smoking cessation patches normally associated with this technology. Further growth in transdermal drug delivery will likely be driven by the continued expansion of biotechnology drugs that require novel delivery methods and by the loss of patent protection for many biopharmaceutical drugs, according to Kalorama’s recently published report “The World Market for Transdermal Drug Delivery”.

Report Details:

The World Market for Transdermal Drug Delivery
Published: September, 2012
Pages: 100
Price: US$ 2.500,00

“Transdermal and transmucosal drug delivery methods greatly enhance patient compliance, especially with the elderly, due to their ease of use,” said Bruce Carlson, publisher of Kalorama Information. “These technologies are also popular with healthcare facilities as they help to reduce possibilities of contamination and infection.”

According to the report, there are several benefits to transdermal drug delivery including continuous, controlled release and absorption of medication into the body and the ability to avoid presystemic metabolism which may occur following oral dosing, including both intestinal and hepatic first-pass metabolism. It can also offer more convenient dosing regimens, such as once or twice weekly dosing, and the ability to quickly discontinue treatment by removal of the patch. ALZA, 3M Pharmaceuticals, Cephalon, Antares Pharma, Labtec GmbH, Apricus Bio, Macrochem are among the companies that sell transdermal drug products or develop technology for them.

To date, there are numerous transdermal products that have gained significant commercial success and provided unique benefits for patients. These include Estraderm (CIBA) for estradiol, Duragesic (Janssen) for fentanyl, Testoderm (ALZA) for testosterone, and Minitran (3M) for nitroglycerin. According to Kalorama’s report, these products and others are driven by advances in biotechnology and molecular biology which have resulted in a large number of novel molecules that would otherwise face significant obstacles in the process of delivery into the patient’s body. Additionally, advancements in materials used for transdermal and transmucosal drug delivery have also had a substantial effect on revenues, according to the report.

The full report has profiles of top companies, a discussion of trends and potential obstacles for marketers, historical market sizes and forecasts, and breakouts for markets by region and by type of disease treated.

More information can be found in the report “The World Market for Transdermal Drug Delivery” by Kalorama Information.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com